Limits...
A cell-targeted chemotherapeutic nanomedicine strategy for oral squamous cell carcinoma therapy.

Wang ZQ, Liu K, Huo ZJ, Li XC, Wang M, Liu P, Pang B, Wang SJ - J Nanobiotechnology (2015)

Bottom Line: Furthermore, Live/Dead assay showed a higher extent of red fluorescence was observed for the cells exposed with PLGA/NR7 than compared with non-targeted PLGA NP.Altogether, our results show the feasibility and promise of a cell-targeted anticancer nanomedicine strategy that can be effective for the treatment of oral squamous cell carcinoma.The present work might be of great importance to the further exploration of the potential application of PLGA/NR7 in the clinically relevant animal models.

View Article: PubMed Central - PubMed

Affiliation: Department of Head and Neck Surgery, Shandong Cancer Hospital and Institute, Jinan, 250117, China. zhiqiwang@126.com.

ABSTRACT

Background: Oral squamous cell carcinoma (OSCC) or cancers of oral cavity is one of the most common cancers worldwide with high rate of mortality and morbidity. At present, chemotherapy is one of the most effective treatments; however it often fails to meet the requirements in the clinical therapy. In the present study, we have successfully formulated ligand-decorated cancer-targeted CDDP-loaded PLGA-PEG/NR7 nanoparticles and demonstrated the feasibility of using NR7 peptide for targeted delivery, rapid intracellular uptake, and enhanced cytotoxic effect in receptor-overexpressed OSCC cancer cells.

Results: Nanosized particles were formed and sustained release patterns were observed for PLGA/NR7 nanoparticles. Significantly higher cellular uptake was observed in HN6 OSCC cancer cells and superior anticancer effects are observed from the optimized targeted nanoparticles. Furthermore, Live/Dead assay showed a higher extent of red fluorescence was observed for the cells exposed with PLGA/NR7 than compared with non-targeted PLGA NP. The presence of the NR7-targeting moiety on the surface of PLGA carriers could allow the specific receptor-mediated internalization, enhanced cellular uptake, and higher cell killing potency. Especially, PLGA/NR7 NP exhibited a superior apoptosis effect in HN6 cancer cells with around ~45 % (early and late apoptotic stage) and ~59 % after 24 and 48 h incubation, respectively. It is apparent that the actively targeted micelles will deliver more anticancer agent to cancer cell than non-targeted one.

Conclusion: Altogether, our results show the feasibility and promise of a cell-targeted anticancer nanomedicine strategy that can be effective for the treatment of oral squamous cell carcinoma. The present work might be of great importance to the further exploration of the potential application of PLGA/NR7 in the clinically relevant animal models.

No MeSH data available.


Related in: MedlinePlus

a Cytotoxicity assay of blank nanoparticles in HN6 cancer cells. b Cytotoxicity analysis of free CDDP, PLGA NP, and PLGA/NR7 NP in HN6 cancer cells. Different amounts of formulations were added from 0.001 to 100 µg/ml to each well and incubated for 24 and 48 h. Survival rate of HN6 cell was determined by MTT assay. Data were obtained from three independent triplicate experiments and were presented as mean ± S.D. **p < 0.01 is the statistical difference between the cytotoxicity of PLGA/NR7 and CDDP
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4591064&req=5

Fig5: a Cytotoxicity assay of blank nanoparticles in HN6 cancer cells. b Cytotoxicity analysis of free CDDP, PLGA NP, and PLGA/NR7 NP in HN6 cancer cells. Different amounts of formulations were added from 0.001 to 100 µg/ml to each well and incubated for 24 and 48 h. Survival rate of HN6 cell was determined by MTT assay. Data were obtained from three independent triplicate experiments and were presented as mean ± S.D. **p < 0.01 is the statistical difference between the cytotoxicity of PLGA/NR7 and CDDP

Mentions: The anticancer efficacy of free CDDP, PLGA NP, and PLGA/NR7 NP was evaluated on squamous cell carcinoma (HN6) using MTT assay. The cells were treated with individual formulations at various concentrations and incubated for 24 and 48 h, respectively. First, blank nanoparticle was incubated in HN6 cells and noted its cytotoxic effect. As seen from Fig. 5a, blank polymer did not induce any appreciable toxicity and the cell viability remained more than 95 % throughout all the concentrations tested. The high cell viability of blank polymer indicates its excellent biocompatibility and would be suitable for the systemic administration or cancer targeting.Fig. 5


A cell-targeted chemotherapeutic nanomedicine strategy for oral squamous cell carcinoma therapy.

Wang ZQ, Liu K, Huo ZJ, Li XC, Wang M, Liu P, Pang B, Wang SJ - J Nanobiotechnology (2015)

a Cytotoxicity assay of blank nanoparticles in HN6 cancer cells. b Cytotoxicity analysis of free CDDP, PLGA NP, and PLGA/NR7 NP in HN6 cancer cells. Different amounts of formulations were added from 0.001 to 100 µg/ml to each well and incubated for 24 and 48 h. Survival rate of HN6 cell was determined by MTT assay. Data were obtained from three independent triplicate experiments and were presented as mean ± S.D. **p < 0.01 is the statistical difference between the cytotoxicity of PLGA/NR7 and CDDP
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4591064&req=5

Fig5: a Cytotoxicity assay of blank nanoparticles in HN6 cancer cells. b Cytotoxicity analysis of free CDDP, PLGA NP, and PLGA/NR7 NP in HN6 cancer cells. Different amounts of formulations were added from 0.001 to 100 µg/ml to each well and incubated for 24 and 48 h. Survival rate of HN6 cell was determined by MTT assay. Data were obtained from three independent triplicate experiments and were presented as mean ± S.D. **p < 0.01 is the statistical difference between the cytotoxicity of PLGA/NR7 and CDDP
Mentions: The anticancer efficacy of free CDDP, PLGA NP, and PLGA/NR7 NP was evaluated on squamous cell carcinoma (HN6) using MTT assay. The cells were treated with individual formulations at various concentrations and incubated for 24 and 48 h, respectively. First, blank nanoparticle was incubated in HN6 cells and noted its cytotoxic effect. As seen from Fig. 5a, blank polymer did not induce any appreciable toxicity and the cell viability remained more than 95 % throughout all the concentrations tested. The high cell viability of blank polymer indicates its excellent biocompatibility and would be suitable for the systemic administration or cancer targeting.Fig. 5

Bottom Line: Furthermore, Live/Dead assay showed a higher extent of red fluorescence was observed for the cells exposed with PLGA/NR7 than compared with non-targeted PLGA NP.Altogether, our results show the feasibility and promise of a cell-targeted anticancer nanomedicine strategy that can be effective for the treatment of oral squamous cell carcinoma.The present work might be of great importance to the further exploration of the potential application of PLGA/NR7 in the clinically relevant animal models.

View Article: PubMed Central - PubMed

Affiliation: Department of Head and Neck Surgery, Shandong Cancer Hospital and Institute, Jinan, 250117, China. zhiqiwang@126.com.

ABSTRACT

Background: Oral squamous cell carcinoma (OSCC) or cancers of oral cavity is one of the most common cancers worldwide with high rate of mortality and morbidity. At present, chemotherapy is one of the most effective treatments; however it often fails to meet the requirements in the clinical therapy. In the present study, we have successfully formulated ligand-decorated cancer-targeted CDDP-loaded PLGA-PEG/NR7 nanoparticles and demonstrated the feasibility of using NR7 peptide for targeted delivery, rapid intracellular uptake, and enhanced cytotoxic effect in receptor-overexpressed OSCC cancer cells.

Results: Nanosized particles were formed and sustained release patterns were observed for PLGA/NR7 nanoparticles. Significantly higher cellular uptake was observed in HN6 OSCC cancer cells and superior anticancer effects are observed from the optimized targeted nanoparticles. Furthermore, Live/Dead assay showed a higher extent of red fluorescence was observed for the cells exposed with PLGA/NR7 than compared with non-targeted PLGA NP. The presence of the NR7-targeting moiety on the surface of PLGA carriers could allow the specific receptor-mediated internalization, enhanced cellular uptake, and higher cell killing potency. Especially, PLGA/NR7 NP exhibited a superior apoptosis effect in HN6 cancer cells with around ~45 % (early and late apoptotic stage) and ~59 % after 24 and 48 h incubation, respectively. It is apparent that the actively targeted micelles will deliver more anticancer agent to cancer cell than non-targeted one.

Conclusion: Altogether, our results show the feasibility and promise of a cell-targeted anticancer nanomedicine strategy that can be effective for the treatment of oral squamous cell carcinoma. The present work might be of great importance to the further exploration of the potential application of PLGA/NR7 in the clinically relevant animal models.

No MeSH data available.


Related in: MedlinePlus